{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:46:11Z","timestamp":1792799171690,"version":"4.5.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Vancomycin is frequently used to treat methicillin-resistant <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic> infections in pediatric patients. Vancomycin exposure may lead to an increase in frequency of nephrotoxicity. Our aim was to conduct a systematic review to describe predictors of nephrotoxicity associated with vancomycin, including documented trough concentrations \u226515\u2009mg\/L. We also aimed to use a meta-analysis to assess the impact of a vancomycin trough \u226515\u2009mg\/L on nephrotoxicity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A literature search was performed using PubMed, Cochrane Library, Embase and Web of Sciences database. We included randomized clinical trials and observational studies evaluating the relationship between vancomycin troughs and nephrotoxicity in pediatric-age patients. Studies not measuring troughs or defining a different cut-off point than 15\u2009mg\/L were excluded. Data on age, exclusion criteria, nephrotoxicity definition, risk factors for nephrotoxicity and vancomycin trough levels were extracted from selected papers.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Ten studies were identified for meta-analysis. All subjects had comparatively normal baseline serum creatinine values. Common risk factors identified included elevated (\u226515\u2009mg\/L) trough levels, renal impairment, hypovolemia and concurrent use of nephrotoxic medications. Troughs \u226515\u2009mg\/L increased nephrotoxicity by 2.7-fold (odds ratio (OR), 2.71; 95% confidence interval: 1.82\u20134.05; <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup> = 40%; <jats:italic toggle=\"yes\">Q<\/jats:italic> = 0.09). These odds were further increased among patients in the pediatric intensive care unit (OR, 3.61; 95% confidence interval: 1.21\u201310.74; <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup> = 45%; <jats:italic toggle=\"yes\">Q<\/jats:italic> = 0.18).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Though the rate of vancomycin-induced nephrotoxicity is increased in pediatric patients with higher vancomycin troughs, other factors such as intensive care unit admission, hypovolemia and concurrent nephrotoxic drug use appear to contribute to the development of nephrotoxicity.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000001882","type":"journal-article","created":{"date-parts":[[2017,12,27]],"date-time":"2017-12-27T17:07:25Z","timestamp":1514394445000},"page":"654-661","source":"Crossref","is-referenced-by-count":63,"title":["Nephrotoxicity With Vancomycin in the Pediatric Population"],"prefix":"10.1097","volume":"37","author":[{"given":"Theresa M.","family":"Fiorito","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Hasbro Children's Hospital"},{"name":"Division of Infectious Diseases, Warren Alpert Medical School of Brown University, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan K.","family":"Luther","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, University of Rhode Island, College of Pharmacy, Kingston, Rhode Island"},{"name":"Infectious Diseases Research Program, Veterans Affairs Medical Center, Providence, Rhode Island."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penelope H.","family":"Dennehy","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hasbro Children's Hospital"},{"name":"Division of Infectious Diseases, Warren Alpert Medical School of Brown University, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry L.","family":"LaPlante","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Warren Alpert Medical School of Brown University, Providence, Rhode Island"},{"name":"Department of Pharmacy Practice, University of Rhode Island, College of Pharmacy, Kingston, Rhode Island"},{"name":"Infectious Diseases Research Program, Veterans Affairs Medical Center, Providence, Rhode Island."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly L.","family":"Matson","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, University of Rhode Island, College of Pharmacy, Kingston, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230912","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1086\/491709","article-title":"Vancomycin: a history.","volume":"42","author":"Donald","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R2-20230912","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1128\/AAC.19.2.306","article-title":"Effects of vancomycin on renal function in rats.","volume":"19","author":"Aronoff","year":"1981","journal-title":"Antimicrob Agents Chemother"},{"key":"R3-20230912","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1128\/AAC.23.1.138","article-title":"Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981.","volume":"23","author":"Farber","year":"1983","journal-title":"Antimicrob Agents Chemother"},{"key":"R4-20230912","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/phar.1227","article-title":"Nephrotoxicity in patients with vancomycin trough concentrations of 15-20 \u03bcg\/ml in a pediatric intensive care unit.","volume":"33","author":"Cies","year":"2013","journal-title":"Pharmacotherapy"},{"key":"R5-20230912","first-page":"360","article-title":"Vancomycin population pharmacokinetics in neonates.","volume":"67","author":"de Hoog","year":"2000","journal-title":"Clin Pharmacokinet"},{"issue":"4 suppl","key":"R6-20230912","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.1097\/CCM.0b013e318168e375","article-title":"An overview of drug-induced acute kidney injury.","volume":"36","author":"Pannu","year":"2008","journal-title":"Crit Care Med"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/INF.0b013e3181db7398","article-title":"Use of vancomycin in pediatrics.","volume":"29","author":"Dehority","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"R8-20230912","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s00228-012-1259-9","article-title":"Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review.","volume":"68","author":"Elyasi","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"R9-20230912","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1177\/0897190014546114","article-title":"Vancomycin nephrotoxicity: a review.","volume":"27","author":"Mergenhagen","year":"2014","journal-title":"J Pharm Pract"},{"key":"R10-20230912","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/phar.1259","article-title":"Acute kidney injury during vancomycin therapy in critically ill children.","volume":"33","author":"Totapally","year":"2013","journal-title":"Pharmacotherapy"},{"key":"R11-20230912","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"R12-20230912","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.clinthera.2010.03.005","article-title":"Prediction of vancomycin pharmacodynamics in children with invasive methicillin-resistant Staphylococcus aureus infections: a Monte Carlo simulation.","volume":"32","author":"Frymoyer","year":"2010","journal-title":"Clin Ther"},{"key":"R13-20230912","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1097\/INF.0b013e318299f75c","article-title":"Desired vancomycin trough serum concentration for treating invasive methicillin-resistant Staphylococcal infections.","volume":"32","author":"Frymoyer","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R14-20230912","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/FTD.0000000000000190","article-title":"Evaluation of target attainment of vancomycin area under the curve in children with methicillin-resistant Staphylococcus aureus bacteremia.","volume":"37","author":"Hahn","year":"2015","journal-title":"Ther Drug Monit"},{"key":"R15-20230912","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1097\/INF.0b013e318286378e","article-title":"Improved vancomycin dosing in children using area under the curve exposure.","volume":"32","author":"Le","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R16-20230912","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/INF.0000000000000991","article-title":"Healthcare-associated Staphylococcus aureus bacteremia in children: evidence for reverse vancomycin creep and impact of vancomycin trough values on outcome.","volume":"35","author":"McNeil","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"R17-20230912","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/pbc.22601","article-title":"Risk factors for renal failure in pediatric patients with acute myeloid leukemia: a retrospective cohort study.","volume":"55","author":"Fisher","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"R18-20230912","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/jpids\/pit076","article-title":"Are elevated vancomycin serum trough concentrations achieved within the first 7 days of therapy associated with acute kidney injury in children?","volume":"3","author":"Knoderer","year":"2014","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R19-20230912","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1177\/1060028015594190","article-title":"Late-occurring vancomycin-associated acute kidney injury in children receiving prolonged therapy.","volume":"49","author":"Knoderer","year":"2015","journal-title":"Ann Pharmacother"},{"key":"R20-20230912","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/phar.1552","article-title":"Assessment of initial serum vancomycin trough concentrations and their association with initial empirical weight-based vancomycin dosing and development of nephrotoxicity in children: a multicenter retrospective study.","volume":"35","author":"Matson","year":"2015","journal-title":"Pharmacotherapy"},{"key":"R21-20230912","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40121-013-0004-8","article-title":"Incidence and predisposing factors of vancomycin-induced nephrotoxicity in children.","volume":"2","author":"Ragab","year":"2013","journal-title":"Infect Dis Ther"},{"key":"R22-20230912","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1097\/MPH.0000000000000470","article-title":"Vancomycin therapeutic targets and nephrotoxicity in critically ill children with cancer.","volume":"38","author":"Seixas","year":"2016","journal-title":"J Pediatr Hematol Oncol"},{"key":"R23-20230912","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1177\/1060028014549185","article-title":"Factors associated with acute kidney injury in children receiving vancomycin.","volume":"48","author":"Sinclair","year":"2014","journal-title":"Ann Pharmacother"},{"key":"R24-20230912","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/jcph.653","article-title":"Pharmacokinetic characteristics and clinical outcomes of vancomycin in young children with various degrees of renal function.","volume":"56","author":"Zhang","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"R27-20230912","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3390\/pharmacy2040276","article-title":"Antimicrobial renal injury in a pediatric intensive care unit: \u03b2-lactams vs. vancomycin.","volume":"2","author":"Cies","year":"2014","journal-title":"Pharmacy"},{"key":"R28-20230912","doi-asserted-by":"crossref","first-page":"E6","DOI":"10.1111\/chd.12187","article-title":"Vancomycin-associated acute kidney injury in pediatric cardiac intensive care patients.","volume":"10","author":"Moffett","year":"2015","journal-title":"Congenit Heart Dis"},{"key":"R29-20230912","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jpeds.2010.08.019","article-title":"Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children.","volume":"158","author":"McKamy","year":"2011","journal-title":"J Pediatr"},{"key":"R30-20230912","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1542\/hpeds.2014-0019","article-title":"Evaluation of vancomycin dosing and corresponding drug concentrations in pediatric patients.","volume":"4","author":"Geerlof","year":"2014","journal-title":"Hosp Pediatr"},{"key":"R31-20230912","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1093\/jpids\/piu110","article-title":"Pharmacodynamic characteristics of nephrotoxicity associated with vancomycin use in children.","volume":"4","author":"Le","year":"2015","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R32-20230912","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/jcpt.12437","article-title":"Retrospective analysis of vancomycin treatment outcomes in Chinese paediatric patients with suspected Gram-positive infection.","volume":"41","author":"Wei","year":"2016","journal-title":"J Clin Pharm Ther"},{"key":"R33-20230912","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1611391","article-title":"Epidemiology of acute kidney injury in critically ill children and young adults.","volume":"376","author":"Kaddourah","year":"2017","journal-title":"N Engl J Med"},{"key":"R34-20230912","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jcf.2013.03.005","article-title":"A review of renal disease in cystic fibrosis.","volume":"12","author":"Nazareth","year":"2013","journal-title":"J Cyst Fibros"},{"key":"R35-20230912","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S0046-8177(82)80056-7","article-title":"The nephropathy of cystic fibrosis: a human model of chronic nephrotoxicity.","volume":"13","author":"Abramowsky","year":"1982","journal-title":"Hum Pathol"},{"key":"R36-20230912","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3109\/00365528809090220","article-title":"Investigation of aminoglycoside nephrotoxicity in cystic fibrosis patients.","volume":"143","author":"Godson","year":"1988","journal-title":"Scand J Gastroenterol Suppl"},{"key":"R37-20230912","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/j.1875-9114.2011.01017.x","article-title":"Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort.","volume":"32","author":"Kullar","year":"2012","journal-title":"Pharmacotherapy"},{"key":"R38-20230912","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2165\/00003088-200443130-00005","article-title":"Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.","volume":"43","author":"Moise-Broder","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"R39-20230912","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/clinids\/18.4.533","article-title":"Serum vancomycin concentrations: reappraisal of their clinical value.","volume":"18","author":"Cant\u00fa","year":"1994","journal-title":"Clin Infect Dis"},{"key":"R40-20230912","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2165\/00002018-199920030-00005","article-title":"Antibacterial-induced nephrotoxicity in the newborn.","volume":"20","author":"Fanos","year":"1999","journal-title":"Drug Saf"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006454-201807000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T22:10:08Z","timestamp":1694556608000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201807000-00008"}},"subtitle":["A Systematic Review and Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000001882","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]}}}